In nucleotide analogs, naive patients with chronic HBV infection who have an AA genotype of the HLA-DQA1/DRB1 gene are more likely to develop HCC during entecavir treatment (Kozuka et al., 2018). The gene discussed is HLA-DRB1; the disease is hepatocellular carcinoma.